Minimizing side effects Several strategies reduce the likelihood and severity of side effects: Start low and titrate up
Fractions containing the desired product were collected, combined, and freeze-dried to afford the product (15 mg) as a pale yellow solid
Z., Sever M., Vidovic T., Lojo N., Kolenc D., Vuletic L
A 2025 real-world cohort study on the risk of vestibular disorders with semaglutide reported that 15% of patients experienced dizziness after starting treatment, indicating this is not a rare, anecdotal complaint but a pattern clinicians should expect
Expect to see: More combination products, such as compounded cagrilintide with semaglutide Expanded research into retatrutide synergy Personalized titration schedules based on pharmacogenomics and metabolic profiling Who Should Consider Cagrilintide Peptides